6,678 trials
Opioid Overdose
Primary: Rate of Fatal Opioid Overdose — 2; 6 Participants
Barrett's Esophagus · Obesity
Primary: Change in Serum PGE2 Levels — 4.44; -21.65 Percentage of change in serum PGE2 level
Wet Macular Degeneration
Primary: Area of Lesion Measured by Optical Coherence Tomography Angiography (OCTA) Scan. — 1.07 mm^2
Preeclampsia · Labor, Premature
Primary: Cesarean Delivery Rate — 29; 22 Participants
Asthma
Primary: Growth Velocity (Centimeter Per Year) Over the Double-blind Treatment Period, as Determined by Stadiometry — 6.065; 5.905 Centimeter per year
End Stage Renal Disease
Primary: Number of Participants With Treatment-related Adverse Events and Treatment Failure — 2; 2; 1; 1 Participants
Body Fat Disorder
Primary: The Proportion of Subjects Who Have at Least a 1-grade Improvement on the Clinician Reported Submental Fat Rating Scale (CR-SMFRS) at the Final Follow-up Visit When…
Urinary Tract Infections
Primary: Urinary Tract Infection — 11; 12 UTI
Vaginal Atrophy
Primary: Vulvar Assessment Scale (VUAS) — 0.10; 0.20 score on a scale
Knee Osteoarthritis · Primary Total Knee Arthroplasty · Physical Therapy
Primary: Number of Participants Able to Hyperextend the Knee After Surgery — 4; 3 Participants
Smoking Cessation
Primary: Rate of Participant Retention — 23; 29; 18; 10 Participants
Systemic Lupus Erythematosus (SLE) · Juvenile SLE · Cutaneous Lupus
Primary: Serum Levels of Thalidomide — 415.1 ng/mL
Hepatitis C · Hemodialysis · Nosocomial Infection
Primary: SVR - Sustained Virologic Response — 3; 0; 1; 0 Participants
Cardiopulmonary Arrest · Respiratory Arrest
Primary: Survival at Day 7 — 306; 336 Participants
Brain Neoplasms · Brain Cancer · Brain Tumors
Primary: Change in Neurotoxicity Scale Scores — -1; -3.5 score on scale — p=0.7824